0.7396
iBio Inc Aktie (IBIO) Neueste Nachrichten
What analysts say about iBio Inc. stockFree Investment Timing Strategies - Autocar Professional
What drives iBio Inc. stock priceSkyrocketing profit margins - Autocar Professional
iBio Inc. Stock Analysis and ForecastFree Investment Case Studies - jammulinksnews.com
Is iBio Inc. a good long term investmentExplosive earning power - jammulinksnews.com
how ibio stock performs during market volatilityFree Short-Term Stock Picks - Newser
what makes ibio inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
What institutions are buying iBio Inc. stock nowFree Access to Investment Community - Newser
Why iBio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
What makes iBio Inc. stock price move sharplyChart Based Entries - Newser
IBIO’s Market Whiplash: -61.36% YTD Decline, -20.36% Plunge in 30 Days - investchronicle.com
How iBio Inc. stock performs during market volatilityFree Access to Investors Club - Newser
iBio (NYSEMKT:IBIO) Stock Price Down 0% – What’s Next? - Defense World
iBio stock soars after amylin receptor antibody shows promising results - Investing.com
iBio Advances Obesity Care with Antibody Therapies - TipRanks
iBio (IBIO) Reports Promising Preclinical Results in Obesity Stu - GuruFocus
iBio stock soars after amylin receptor antibody shows promising results By Investing.com - Investing.com UK
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agon - GuruFocus
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - Yahoo Finance
iBio Extends Promissory Note Maturity to 2026 - TipRanks
Ibio nominates IBIO-610 as obesity development candidate - BioWorld MedTech
iBio initiates primate study for obesity antibody candidate IBIO-610 By Investing.com - Investing.com South Africa
iBio (IBIO) Begins Preclinical Study of New Antibody Candidate | - GuruFocus
iBio initiates primate study for obesity antibody candidate IBIO-610 - Investing.com
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | IBIO Stock News - GuruFocus
iBio initiates non-human primate study of IBIO-610 - TipRanks
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - The Manila Times
Breakthrough Obesity Drug Shows 77% Fat Reduction When Combined With GLP-1 Treatments - Stock Titan
iBio (IBIO) Plans to Offer 11.25 Million Shares of Common Stock - GuruFocus
Sector Update: Health Care - MarketScreener
IBio Files Prospectus for Resale of About 11.3 Million Shares - marketscreener.com
Plant-Based Vaccines Market Future Business Opportunities 2025-2032 | Medicago, Inc., IBIO, Icon Genetics GmbH - newstrail.com
iBio: University of Limerick programme to ‘shape the next generation’ of pharmaceutical manufacturing experts - University of Limerick
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Plant-Based Vaccines Market Detailed In New Research Report - openPR.com
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):